Market Place
Sourcing Support
BioAge Labs To Present At Needham Healthcare Conference
13 Apr 2026 //
GLOBENEWSWIRE
BioAge Labs Reports 2025 Financials, Q4 Updates
24 Mar 2026 //
GLOBENEWSWIRE
BioAge Labs To Present At Oppenheimer Healthcare Conference
19 Feb 2026 //
GLOBENEWSWIRE
BioAge Expands BGE-102`s Indication to Diabetic Macular Edema
20 Jan 2026 //
GLOBENEWSWIRE
BioAge Announces Positive Phase 1 Data for BGE-102
12 Jan 2026 //
GLOBENEWSWIRE
BioAge Announces Positive Phase 1 Data for BGE-102
04 Dec 2025 //
GLOBENEWSWIRE
Bioage Labs To Present At Piper Sandler Healthcare Conference
25 Nov 2025 //
GLOBENEWSWIRE
Bioage Labs To Present At Jefferies Global Healthcare Conference
07 Nov 2025 //
GLOBENEWSWIRE
Bioage Labs Reveals Q3 2025 Financials & Business Updates
06 Nov 2025 //
GLOBENEWSWIRE
BioAge & HitGen Begin Phase 1 Study of BGE-102, NLRP3 Inhibitor
15 Sep 2025 //
PR NEWSWIRE
BioAge Labs Set to Speak at Future Investor Conferences
20 Aug 2025 //
GLOBENEWSWIRE
BioAge Starts Ph 1 of BGE-102, Brain-Penetrant NLRP3 Inhibitor
15 Aug 2025 //
GLOBENEWSWIRE
BioAge Labs Reports Q2 2025 Financials and Updates on Business
06 Aug 2025 //
GLOBENEWSWIRE
BioAge Expands Platform Using Leading EU Biobank Data
17 Jun 2025 //
GLOBENEWSWIRE
BioAge inks Option Agreement for Chinese biotech`s Obesity Asset
04 Jun 2025 //
FIERCE BIOTECH
BioAge Labs completes IND studies for BGE-102, A Brain-Penetrant
29 May 2025 //
GLOBENEWSWIRE
BioAge Labs to Present at Upcoming Investor Conferences
27 May 2025 //
GLOBENEWSWIRE
BioAge Labs Reports Q1 2025 Financial Results, Business Updates
06 May 2025 //
GLOBENEWSWIRE
BioAge Labs Reports 2024 Financial Results and Business Updates
20 Mar 2025 //
GLOBENEWSWIRE
Novartis, BioAge take on age-related diseases in $550M pact
19 Dec 2024 //
FIERCE BIOTECH
BioAge secures Novartis deal worth up to $550M biobucks
18 Dec 2024 //
FIERCE BIOTECH
BioAge obesity study derailed by side effects 2 months after IPO
09 Dec 2024 //
FIERCE BIOTECH
BioAge scraps mid-stage trial of obesity drug, shares fall
09 Dec 2024 //
REUTERS
BioAge Labs Reports Q3 2024 Financial Results & Business Updates
07 Nov 2024 //
GLOBENEWSWIRE
BioAge Labs Presents Preclinical Azelaprag Data at ObesityWeek 2024
04 Nov 2024 //
GLOBENEWSWIRE
BioAge Announces Plans for Phase 2 of BGE-105 Co-Administered With Tirzepatide
26 Oct 2023 //
BUSINESSWIRE
Lilly, BioAge to test muscle regeneration drug with tirzepatide
26 Oct 2023 //
FIERCE BIOTECH
